Abstract:OBJECTIVE To investigate the role and mechanism of action of fibroblast growth factor-21 (FGF-21) in reducing triglyceride (TG) in the in vitro and in vivo models of nonalcoholic fatty liver disease (NAFLD). METHODS (1) A mixture of free fatty acids was used to establish a model of steatosis in L02 cells, and the cells were treated with various concentrations of FGF-21 or fenofibrate. Twenty-four hours later, oil red O staining was performed to observe the degree of steatosis, and intracellular TG content was determined. RT-PCR and Western blot were applied to measure the mRNA and protein expression of sterol regulatory element-binding protein-1c (SREBP-1c). (2) High-fat diet was used to establish a mouse model of steatosis, and these mice were intraperitoneally injected with FGF-21 or fenofibrate. Eight weeks later, whole blood and liver samples were collected, and HE staining was performed to observe steatosis. Meanwhile, the serum levels of TG, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured, and TG content in the liver was also measured. One-way analysis of variance was used for comparison of data between multiple groups, and the least significant difference t-test was used for comparison between any two groups. RESULTS (1) Compared with the control group, the model group showed significant steatosis, with significant increases in intracellular lipid droplets and TG content (t = -20.57, P < 0.01), while FGF-21 reduced the number of intracellular lipid droplets and TG content (F = 98.16, P < 0.01) in a dose-dependent manner. In addition, the model group had significantly increased mRNA and protein expression of SREBP-1c compared with the control group (t = -10.73 and -0.1006, both P < 0.01), while FGF-21 down-regulated the mRNA and protein expression of SREBP-1c (F = 161.35 and 36.72, both P < 0.01). (2) Compared with the mice in the control group, those in the model group showed significant steatosis and had significant increases in serum TG level and TG content in the liver (t = -18.84 and 15.71, both P < 0.01). FGF-21 relieved hepatic steatosis and reduced the serum TG level and TG content in the liver (t = 18.11 and 9.46, both P < 0.01). Moreover, FGF-21 reduced the serum levels of ALT and AST in NAFLD mice (t = 25.93 and 12.50, both P < 0.01). CONCLUSION FGF-21 can inhibit the synthesis of TG through suppressing the expression of SREBP-1c, which further confirms the potential therapeutic effect of FGF-21 in the treatment of NAFLD. This may provide new ideas for the treatment of NAFLD.

Dose–response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease

High Circulating Fibroblast Growth Factor-21 Levels as a Prognostic Marker in Fatty Pancreas Patients

High circulating fibroblast growth factor-21 levels as a screening marker in fatty pancreas patients

Fibroblast Growth Factor 21 Levels Are Increased in Nonalcoholic Fatty Liver Disease Patients and Are Correlated with Hepatic Triglyceride

Association Between Serum Free Fatty Acid Levels and Nonalcoholic Fatty Liver Disease: a Cross-Sectional Study

High Serum Level of Fibroblast Growth Factor 21 is an Independent Predictor of Non-Alcoholic Fatty Liver Disease: A 3-Year Prospective Study in China

Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study

Clinical significance of serum FGF21 levels in diagnosing nonalcoholic fatty liver disease early

Serum Fetuin A Level is Associated with Nonalcoholic Fatty Liver Disease in Chinese Population

Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.

Fibroblast growth factor 21 in non-alcoholic fatty liver disease

Insight to the Association among Fibroblast Growth Factor 21, Non-Alcoholic Fatty Liver Disease and Cardiovascular Outcomes: A Population-Based Study.

[Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease].

Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease

Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events

Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study.

Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis

Serum Fibroblast Growth Factor 21 is Associated with Adverse Lipid Profiles and Gamma-Glutamyltransferase but Not Insulin Sensitivity in Chinese Subjects

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

Relationship of postprandial fibroblast growth factor 21 with lipids, inflammation and metabolic dysfunction-associated fatty liver disease during oral fat tolerance test

The Role of Fibroblast Growth Factor 21 in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Implications for Therapy